MPL and autoimmune thrombocytopenic purpura: Among the innovative molecules under investigations for their emerging iron chelating properties, eltrombopag (ELT), the thrombopoietin receptor agonist used in immunethrombocytopenia (ITP) and aplastic anemia, shows anticancer properties related to its iron chelating properties [23], even though the possibility of using it is not yet concrete [24, 25, 32].